SFE Investment Counsel Buys 3,271 Shares of Johnson & Johnson (NYSE:JNJ)

SFE Investment Counsel raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,727 shares of the company's stock after purchasing an additional 3,271 shares during the period. SFE Investment Counsel's holdings in Johnson & Johnson were worth $5,262,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $26,000. Conquis Financial LLC bought a new stake in shares of Johnson & Johnson during the 4th quarter worth $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the fourth quarter worth $36,000. Highline Wealth Partners LLC lifted its stake in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Finally, von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the first quarter worth $49,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.3%

JNJ traded up $0.52 during midday trading on Thursday, reaching $169.62. The company's stock had a trading volume of 6,629,361 shares, compared to its average volume of 8,401,730. The firm has a market capitalization of $408.11 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 2.15 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock's 50-day moving average is $155.75 and its 200-day moving average is $155.63.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. The business's revenue for the quarter was up 5.8% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's payout ratio is 55.61%.

Wall Street Analyst Weigh In

Several analysts have weighed in on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim boosted their price objective on shares of Johnson & Johnson from $164.00 to $167.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.